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  45 
Abstract  46 
We examined the effects of graded muscle glycogen on exercise capacity and modulation of 47 
skeletal muscle signalling pathways associated with the regulation of mitochondrial biogenesis. 48 
In a repeated measures design, eight males completed a sleep-low, train-low model comprising 49 
an evening glycogen depleting cycling protocol followed by an exhaustive exercise capacity 50 
test (8 x 3 min at 80% PPO, followed by 1 min efforts at 80% PPO until exhaustion) the 51 
subsequent morning. Following glycogen depleting exercise, subjects ingested a total of 0 g 52 
kg-1 (L-CHO), 3.6 g kg-1 (M-CHO) or 7.6 g kg-1 (H-CHO) of carbohydrate during a 6 h period 53 
prior to sleeping, such that exercise was commenced the next morning with graded (P < 0.05) 54 
muscle glycogen concentrations (Mean ± SD) (L-CHO: 88 ± 43, M-CHO: 185 ± 62, H-CHO: 55 
278 ± 47 mmol kg-1 dw). Despite differences (P < 0.05) in exercise capacity at 80% PPO 56 
between trials (L-CHO: 18 ± 7, M-CHO: 36 ± 3, H-CHO: 44 ± 9 min) exercise induced 57 
comparable AMPKThr172 phosphorylation (~4 fold) and PGC-1α mRNA expression (~5 fold) 58 
post- and 3 h post-exercise, respectively. In contrast, exercise nor CHO availability affected 59 
the phosphorylation of p38MAPKThr180/Tyr182, CaMKIIThr268 or mRNA expression of p53, Tfam, 60 
CPT-1, CD36 or PDK4 Data demonstrate that when exercise is commenced with muscle 61 
glycogen below 300 mmol kg-1 dw, further graded reductions of 100 mmol kg-1 dw impairs 62 
exercise capacity but does not augment skeletal muscle cell signaling.  63 
 64 
Keywords: muscle glycogen, mitochondrial biogenesis, train low, exercise capacity    65 
New & Noteworthy  66 
We provide novel data demonstrating that when exercise is commenced with muscle glycogen 67 
below 300 mmol kg-1 dw (as achieved using the sleep-low, train-low model) further graded 68 
reductions in pre-exercise muscle glycogen of 100 mmol kg-1 dw reduces exercise capacity at 69 
80% PPO by 20-50% but does not augment skeletal muscle cell signalling. 70 
 71 
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 91 
Introduction 92 
Skeletal muscle glycogen is recognised as the predominant energy substrate used during 93 
endurance exercise (14) and plays an important role in regulating the capacity to sustain 94 
exercise at a given workload (4, 13, 16). Additionally, muscle glycogen acts as a regulatory 95 
molecule (32) that is able to modulate cell signalling and transcriptional responses to exercise 96 
and subsequently augment selected skeletal muscle markers of training adaptation (e.g 97 
succinate dehydrogenase (29), citrate synthase (12) and β-hydroxyacyl-CoA-dehydrogenase 98 
(18) enzyme activity and cytochrome c oxidase subunit IV content (47)). Most notably, 99 
exercise commenced with reduced muscle glycogen (as defined as a ‘train-low’ session (40)) 100 
augments the AMPK-PGC-1α signaling axis (3, 35, 39, 46) and results in the augmented 101 
expression of target genes with putative roles in the regulation of mitochondrial biogenesis and 102 
substrate utilisation (3, 25, 33). Whilst a multitude of research designs have been used to study 103 
the physiological and molecular responses to ‘train-low’ exercise, the recently developed 104 
‘sleep-low, train-low’ model (which requires athletes to perform an evening training session, 105 
restrict carbohydrate (CHO) during overnight recovery, and then complete a fasted training 106 
session the subsequent morning) provides a potent strategy to augment mitochondrial related 107 
cell signalling (3, 5, 25). Furthermore, repeated bouts of sleep-low, train-low is the only train-108 
low model shown to enhance performance in trained endurance athletes (27, 28).  109 
 110 
Given the enhanced training response associated with the sleep-low, train-low model is 111 
potentially regulated by muscle glycogen availability, it is prudent to consider the absolute 112 
glycogen concentrations required to facilitate this response. In this regard, examination of 113 
available data demonstrate that the augmented signalling and transcriptional responses 114 
associated with train-low models are particularly apparent when absolute pre-exercise muscle 115 
glycogen concentrations are ≤300 mmol kg-1 dw (20). Such data suggest the presence of a 116 
muscle glycogen threshold, whereby a critical absolute level of glycogen must be surpassed in 117 
order to induce the augmented cell signalling responses associated with the train-low model 118 
(33). In accordance with data derived from acute exercise protocols, the notion of a glycogen 119 
threshold is also apparent when investigating selected skeletal muscle markers of training 120 
adaptation (20). For example, train-low sessions commenced with glycogen concentrations < 121 
300 mmol kg-1 dw (12, 29, 47) result in augmented oxidative enzyme activity and/or content 122 
following 3-10 weeks of training. In contrast, when ‘train-low’ sessions are commenced with 123 
markedly higher pre-exercise muscle glycogen concentrations (400-500 mmol kg-1 dw) skeletal 124 
muscle markers of training adaptation are not augmented (11). Nonetheless, whist training with 125 
low muscle glycogen augments selected signalling events, absolute training volume (19) and/or 126 
intensity (18, 24, 47) may be reduced due to a lack of muscle substrate and/or an impairment 127 
in the contractile apparatus of skeletal muscle (10, 30). When taken together, the challenge that 128 
exists is to therefore facilitate the pro-signalling environment whilst simultaneously 129 
maintaining the ability to complete the desired workload and intensity in order to promote 130 
training adaptation.  131 
 132 
With this in mind, the aim of the present study was to examine the effects of graded pre-exercise 133 
glycogen concentrations on both exercise capacity and the modulation of selected skeletal 134 
muscle signalling pathways with putative roles in the regulation of mitochondrial biogenesis. 135 
Our model of graded pre-exercise muscle glycogen was achieved through a sleep-low, train-136 
low model that adopted CHO intakes considered practically viable (within the time-course of 137 
sleep-low designs) and representative of real-world refeeding strategies. Whilst the use of such 138 
sleep-low, train-low models are primarily designed for athletic populations, the use of 139 
recreational populations allows for a greater understanding of the molecular events that occur 140 
in response to such ‘train-low’ designs, given the difficulties of collecting muscle biopsies from 141 
elite athletes. We hypothesised that the activation of skeletal muscle signalling pathways would 142 
be proportionally dependent on pre-exercise muscle glycogen concentrations.   143 
Methods 144 
Participants 145 
Eight recreationally active males (mean ± SD: age, 22 ± 3 years; body mass 76.0 ± 12.7 kg; 146 
height, 177.9 ± 5.7 cm) took part in this study. Mean V̇O2peak and peak power output (PPO) for 147 
the cohort were 48.9 ± 7.0 mL kg-1 min-1 and 273 ± 21 W, respectively. None of the subjects 148 
had any history of musculoskeletal or neurological disease nor were they under any 149 
pharmacological treatment during the course of the testing period. All subjects provided written 150 
informed consent and all procedures conformed to the standards set by the Declaration of 151 
Helsinki (2008). The study was approved by the local Research Ethics Committee of Liverpool 152 
John Moores University.  153 
 154 
Experimental Design  155 
Using a sleep-low, train-low model and a repeated measures design, with each experimental 156 
trial separated by a minimum of 7 days, subjects undertook an evening bout of glycogen 157 
depletion exercise followed by the consumption of graded quantities of CHO (L-CHO: 0 g, M-158 
CHO: 3.6 g kg-1, H-CHO: 7.6g kg-1) across a 6 h period, so that exhaustive exercise was 159 
commenced the next morning with three different levels of pre-exercise muscle glycogen 160 
concentrations. Skeletal muscle biopsies were obtained from the vastus lateralis immediately 161 
before, post- and 3 h post-exercise. During the H-CHO and M-CHO trials, an additional muscle 162 
biopsy was obtained at a matched time point corresponding to the point of exhaustion in the L-163 
CHO trial, allowing for work-matched comparison between trials. Consequently, all subjects 164 
completed the L-CHO trial first, whilst the subsequent M-CHO and H-CHO trials were 165 
completed in a randomised and counterbalanced order. An overview of the experimental 166 
protocol is shown in Figure 1. 167 
 168 
Assessment of peak oxygen uptake 169 
At least 7 days prior to experimental trials, all subjects were assessed for peak oxygen 170 
consumption (V̇O2peak) and peak power output (PPO) on an electronically braked cycle 171 
ergometer (Lode Excalibur Sport, Groningen, Netherlands). Following the completion of a 10 172 
min warm-up at 75 W, the test began at 100 W and consisted of 2 minute stages with 30 W 173 
increments in resistance until volitional exhaustion. V̇O2peak was stated as being achieved by 174 
the following end-point criteria: (1) heart rate within 10 beats min-1 of age-predicted maximum, 175 
(2) respiratory exchange ratio > 1.1 and (3) plateau of oxygen consumption despite increased 176 
workload. Peak aerobic power was taken as the final stage completed during the incremental 177 
test.  178 
 179 
Overview of sleep-low, train-low model 180 
Phase 1: Glycogen depletion exercise 181 
In the 24 h preceding glycogen depleting exercise (i.e. from 12 pm the day prior), subjects 182 
consumed a standardised high CHO diet (8 g kg-1 CHO, 2 g kg-1 protein and 1 g kg-1 fat) and 183 
refrained from alcohol and vigorous physical exercise for the previous 48 h. The standardised 184 
diet consisted of 3 main meals and 3 CHO rich snacks, with subjects required to stop eating 3 185 
h prior to commencing glycogen depleting exercise. On the day of glycogen depleting exercise, 186 
subjects reported to the laboratory at approximately 3 pm to perform a bout of intermittent 187 
glycogen depleting cycling, as previously completed in our laboratory (19, 43). The pattern of 188 
exercise and total time to exhaustion in the subject’s initial trial was recorded and replicated in 189 
all subsequent trials. Subjects were permitted to consume water ad libitum during exercise, 190 
with the pattern of ingestion replicated during subsequent trials.  191 
Phase 2: Carbohydrate re-feeding strategy 192 
To facilitate our overnight sleep-low model, subjects were fed 30 g of whey protein isolate 193 
(Science in Sport, Nelson, UK) mixed with 500 ml of water immediately following the 194 
cessation of glycogen depleting exercise to reflect real-world practice as per current nutritional 195 
guidelines (44). Subjects in the L-CHO trial then refrained from eating for the remainder of the 196 
evening whereas subjects within the M-CHO and H-CHO trials were provided with a mixture 197 
of CHO drinks (Maltodextrin, Science in Sport, Nelson UK) and gels (GO isotonic energy gel, 198 
Science in Sport, Nelson UK) to be consumed at hourly intervals. In the M-CHO trial, subjects 199 
were provided with CHO at a rate of 1.2 g kg-1 h-1 for 3 h whereas subjects in the H-CHO trial 200 
were provided with 1.2 g kg-1 h-1 for 3 h followed by a high carbohydrate meal (4 g kg-1 CHO, 201 
51 ± 1 g protein and 17 ± 1 g fat) consisting of bread, soup, rice, fresh juice, rice pudding and 202 
jam after 4 h of recovery. In this way, total CHO intakes in the L-CHO, M-CHO and H-CHO 203 
trials equated to 0, 3.6 and 7.6 g kg-1, respectively, with fluid intake allowed ad libitum.   204 
 205 
Phase 3: High intensity interval cycling and exercise capacity test 206 
To facilitate our train-low exercise session, subjects arrived the subsequent morning between 207 
8-9 am, in a fasted state, where a venous blood sample was collected from the antecubital vein 208 
and a muscle biopsy taken from the vastus lateralis. Subjects then completed the high-intensity 209 
interval (HIIT) cycling protocol, consisting of 8 x 3 min intervals at 80% PPO, interspersed 210 
with 1 min rest. During exercise, heart rate (HR) was continuously measured and the final HR 211 
for each 3 min interval was recorded, whilst ratings of perceived exertion (RPE) were recorded 212 
upon completion of each interval. Expired gas was collected via a mouthpiece connected to an 213 
online gas analysis system (CPX Ultima, Medgraphics, Minnesota, US) for the final 1.5 min 214 
of each interval and substrate utilisation was assessed using the equations of Jeukendrup & 215 
Wallis (22) given the validity of indirect calorimetry for the assessment of substrate utilisation 216 
at exercise intensities up to 80-85% V̇O2max (37). Upon completion of the high-intensity cycling 217 
protocol, subjects were provided with 5 min of active recovery prior to commencing an exercise 218 
capacity test consisting of intermittent “1 min efforts” corresponding to 80% PPO interspersed 219 
with 1 min recovery periods at 40% PPO. This intermittent protocol was followed until the 220 
subjects reached volitional exhaustion and has been previously utilised in our laboratory (19). 221 
Following the completion of the exercise capacity test and collection of the post-exercise 222 
biopsy, subjects were fed 30 g whey protein (Science in Sport, Nelson, UK) mixed with 500 223 
ml of water. 224 
 225 
Blood analysis 226 
Venous blood samples were collected in vacutainers containing K2EDTA, lithium heparin or 227 
serum separation tubes and stored on ice or at room temperature until centrifugation at 1500 g 228 
for 15 min at 4oC. Samples were collected immediately prior to exercise, at the point of 229 
exhaustion (post exercise) and 3 h post exercise, whilst an additional sample was obtained at a 230 
time point corresponding to the point of exhaustion in the L-CHO trial during the M-CHO and 231 
H-CHO trials. Plasma was aliquoted and stored at -80oC until analysis. Samples were later 232 
analysed for plasma glucose, lactate, non-esterified fatty acids (NEFA) and glycerol using 233 
commercially available enzymatic spectrophotometric assays (RX Daytona Analyser, Randox, 234 
UK) as per manufacturer instructions. 235 
 236 
Muscle biopsies 237 
Skeletal muscle biopsies (~20 mg) were obtained from the vastus lateralis immediately prior 238 
to exercise, at the point of exhaustion (post exercise) and 3 h post exercise. During the M-CHO 239 
and H-CHO trials, an additional muscle biopsy was obtained at a time point corresponding to 240 
the point of exhaustion in the L-CHO trial, thereby allowing for ‘work-matched’ comparison 241 
between trials. For the work-matched biopsy, subjects dismounted the cycle ergometer and 242 
were moved to the adjacent biopsy suite. Following collection of the biopsy sample (~5 min), 243 
subjects recommenced cycling exercise. Muscle biopsies were obtained from separate incision 244 
sites 2-3 cm apart using a Bard Monopty Disposable Core Biopsy Instrument (12 gauge x 10 245 
cm length, Bard Biopsy Systems, Tempe, AZ, USA) under local anaesthesia (0.5% Marcaine) 246 
and immediately frozen in liquid nitrogen and stored at -80oC for later analysis.  247 
 248 
Muscle glycogen concentration  249 
Muscle glycogen concentrations were determined according to the acid hydrolysis method 250 
described by Van Loon et al (26). Approximately 2-5 mg of freeze-dried tissue was powdered, 251 
dissected of all visible blood and connective tissue and subsequently hydrolysed by incubation 252 
in 500 μl of 1 M HCl for 3 h at 95oC. After cooling to room temperature, samples were 253 
neutralised by the addition of 250 μl 0.12 mol L-1 Tris/2.1 mol L-1 KOH saturated with KCl. 254 
Following centrifugation, 200 μl of supernatant was analysed in duplicate for glucose 255 
concentration according to the hexokinase method using a commercially available kit (GLUC-256 
HK; Randox Laboratories, Antrim, UK). Glycogen concentration is expressed as mmol kg-1 257 
dry weight and intra-assay coefficients of variation were <5%. 258 
 259 
RNA isolation and analysis 260 
Muscle samples (~20 mg) were homogenised in 1 ml TRIzol reagent (Thermo Fisher Scientific, 261 
UK) and total RNA isolated according to the manufacturer’s guidelines. Concentrations and 262 
purity of RNA were assessed by UV spectroscopy at optical densities (OD’s) of 260 and 280 263 
nm, using a Nanodrop 3000 (Fisher, Rosklide, Denmark) with an average 260/280 ratio of 1.9 264 
± 0.1. A quantity of 70 ng RNA was used for each 20 μl PCR reaction. 265 
 266 
Reverse transcriptase quantitative Real-Time Polymerase Chain Reaction (rt-qRT-PCR) 267 
RT-PCR amplifications were performed using QuantiFastTM SYBR® Green RT-PCR one-step 268 
kit on a Rotogene 300Q (Qiagen, Crawley, UK) supported by Rotogene software (Hercules, 269 
CA). RT-qTR-PCR was performed as follows: hold 50oC for 10 min (reverse 270 
transcription/cDNA synthesis), 95oC for 5 min (transcriptase inactivation and initial 271 
denaturation step), and PCR steps of 40 cycles; 95oC for 10 sec (denaturation), 60oC for 30 sec 272 
(annealing and extension). Upon completion, dissociation/melting curve analyses were 273 
performed to reveal and exclude nonspecific amplification or primer-dimer issues (all melt 274 
analysis in this study presented single reproducible peaks for each target gene suggesting 275 
amplification of a single product). Following initial screening of suitable reference genes, 276 
GAPDH showed the most stable Ct values across all RT-PCR runs and subjects, regardless of 277 
experimental condition (25.3 ± 1.0) and was therefore selected as the reference gene in all RT-278 
PCR assays. The average PCR efficiency for all RT-PCR runs (90 ± 2%) was similar for all 279 
genes across all time points and experimental conditions. As such, the relative gene expression 280 
levels were calculated using the comparative Ct (ΔΔCt) equation (38) where the relative 281 
expression was calculated as 2-ΔΔct where Ct represents the threshold cycle. mRNA expression 282 
for all target genes was calculated relative to the reference gene (GAPDH) within the same 283 
subject and condition and relative to the pre-exercise value in the H-CHO condition.     284 
    285 
SDS page & Western blotting 286 
Muscle samples (~20 mg) were powdered on dry ice and homogenised (FastPrep-24™ 5G 287 
Instrument) for 2 x 40 s at 6 m.s-1 in 10-fold mass of ice-cold lysis homogenisation buffer (10% 288 
glycerol, 20 mM Na-pyrophosphate, 150 mM NaCl, 50 mM HEPES (pH 7.5), 1% NP-40, 20 289 
mM β-glycerphosphate, 10 mM NaF, 1 mM EDTA (pH 8.8), 1 mM EGTA (pH 8.8), 3 mM 290 
Benzamidine, 1 mM 1,4-Dithiothreitol, 1% Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich), 291 
1% Phosphatase Inhibitor Cocktail 3 (Sigma), 4.8% complete Mini Protease Inhibitor Cocktail 292 
(Roche)). The resulting homogenate was centrifuged at 4°C for 10 min at 8000 g and the 293 
supernatant used for the determination of protein concentrations using the DC protein assay 294 
(Bio-Rad, California, USA). Samples were resuspended in 4X Laemlli buffer, boiled for 5 min 295 
and separated by SDS-PAGE before being transferred to nitrocellulose membranes (Pall Life 296 
Sciences, Pensacola, Florida, USA). Following transfer, membranes were stained for protein 297 
with Ponceau S (Sigma-Aldrich, Gillingham, UK), blocked in TBS-Tween containing 3% non-298 
fat milk for 1 h and incubated overnight in primary antibodies (AMPKα (2603), p-AMPKThr172 299 
(2531), ACC (3676), p-ACCSer79 (3661), p38MAPK (9212), p-p38MAPKThr180/Tyr182 (4511), 300 
CaMKII (3362) and p-CaMKIIThr268 (12716) from Cell Signaling Technologies), before 301 
incubation in relevant secondary antibodies (anti-rabbit (7074) from Cell Signaling 302 
Technologies) for 1 h at room temperature. Proteins were detected via chemiluminescence 303 
(Millipore, Watford, UK) and quantified by densitometry using GeneTools software (Syngene, 304 
Cambridge, UK). Sufficient muscle was available for Western blot analysis for seven subjects. 305 
Data is reported as the phosphorylated protein of interest normalised to total protein and each 306 
timepoint is reported relative to the pre-exercise value in the H-CHO condition.  307 
 308 
Statistical analysis 309 
All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS 310 
Version 24). Comparison of average physiological responses and exercise capacity were 311 
analysed using a one-way repeated-measures general linear model whereas changes in 312 
physiological and molecular responses between conditions (i.e. muscle glycogen, mRNA 313 
expression and activity of signalling molecules) were analysed using a two-way repeated 314 
measures general linear model, where the within factors were time and condition. Here, the 315 
post-exercise sampling point in the L-CHO trial was also used as the work-matched sampling 316 
point as this corresponded to the same sampling point and allowed for comparison between 317 
trials. Where a significant main effect was observed, pairwise comparisons were analysed 318 
according to Bonferroni post-hoc tests in order to locate specific differences. All data in text, 319 
figures and tables are presented as means ± SD with P values ≤ 0.05 indicating statistical 320 
significance.  321 
 322 
Results 323 
Skeletal muscle glycogen and exercise capacity 324 
The exercise and nutritional strategy employed was successful in achieving graded levels of 325 
pre-exercise muscle glycogen (H-CHO; 278 ± 47, M-CHO; 185 ± 62, L-CHO; 88 ± 43 mmol 326 
kg-1 dw) such that exercise was commenced with three distinct levels of muscle glycogen (P = 327 
0.016) (Figure 2A). Exhaustive exercise significantly reduced (P < 0.001) muscle glycogen 328 
concentration to comparable levels (<100 mmol kg-1 dw) with no difference between 329 
conditions (P = 0.11). In accordance with the observed differences in pre-exercise muscle 330 
glycogen concentration, total exercise time spent at 80% PPO in the H-CHO trial (44 ± 9 min) 331 
was significantly greater than both M-CHO (36 ± 3 min) (P = 0.037) and L-CHO (18 ± 6 min) 332 
trials (P < 0.001) whilst the M-CHO trial was significantly greater than the L-CHO trial (P < 333 
0.001) (Figure 2B). Given the low pre-exercise muscle glycogen concentration of subjects in 334 
the L-CHO trial, 6 of the 8 subjects were unable to complete the prescribed HIIT protocol. As 335 
such, exercise capacity data is presented as the total amount of time spent at 80% PPO and is 336 
inclusive of the exercise performed during the prescribed HIIT protocol and subsequent 337 
capacity test and excludes all time spent at rest/recovery.  338 
 339 
Physiological and metabolic responses to exercise 340 
Subject’s average heart rate (Figure 3A) across the HIIT session, when matched for work done 341 
(H-CHO; 163 ± 16, M-CHO; 167 ± 15, L-CHO; 171 ± 17 beats.min-1) was significantly higher 342 
in the L-CHO trial compared with H-CHO (P = 0.031) only. Similarly, subject’s average RPE 343 
(Figure 3B) across the HIIT session (H-CHO; 13 ± 1, M-CHO; 14 ± 1, L-CHO; 16 ± 1 344 
beats.min-1) was significantly higher in the L-CHO trial compared with both M-CHO (P = 345 
0.041) and H-CHO (P = 0.012) trials, respectively. Exhaustive exercise resulted in a significant 346 
reduction in plasma glucose (P = 0.036), where plasma glucose was significantly lower in the 347 
L-CHO trial when compared with the H-CHO trial only (P = 0.015) (Figure 3C). Exhaustive 348 
exercise resulted in a significant increase in plasma lactate (P = 0.001), NEFA (P < 0.001) and 349 
glycerol (P = 0.012) but did not display any significant differences between trials (Figures 3D, 350 
E and F, respectively). However, when matched for work done, plasma NEFA (P = 0.01) and 351 
plasma glycerol (P = 0.017) was increased to a significantly greater extent in the L-CHO trial 352 
when compared with the H-CHO trial only. In addition, subjects in the L-CHO trial oxidised 353 
significantly less CHO (P = 0.048) and greater amounts of lipid (P = 0.004) when compared 354 
with the H-CHO trial only (Figure 3G and H, respectively).  355 
 356 
Regulation of mitochondrial biogenesis related cell signalling  357 
Exhaustive exercise induced significant increases in AMPKThr172 phosphorylation (P = 0.017) 358 
but did not display any significant differences between trials (P = 0.548) (Figure 4A). Similarly, 359 
exhaustive exercise induced significant increases in ACCSer79 phosphorylation (P = 0.005), 360 
although phosphorylation was higher in the M-CHO trial when compared with the L-CHO trial 361 
only (P = 0.021) (Figure 4B). When exercise duration was matched to the post-exercise 362 
sampling point in the L-CHO group, the increase in AMPKThr172 phosphorylation remained 363 
comparable between groups (P = 0.269) and the increase in ACCSer79 phosphorylation still 364 
remained higher in the M-CHO trial when compared with the L-CHO trial (P = 0.021). In 365 
contrast, exhaustive exercise did not induce phosphorylation of p38MAPKThr180/Tyr182 (P = 366 
0.656) (Figure 4C) or CaMKIIThr286 (P = 0.707) (Figure 4D). Representative Western blots are 367 
shown in Figure 4E. With regard to exercise induced gene expression, exhaustive exercise 368 
induced a significant increase in PGC-1α mRNA expression at 3 h post-exercise (P = 0.001) 369 
but did not display any significant differences between trials (Figure 5A). In contrast, p53, 370 
Tfam, CPT-1, CD36 and PDK4 mRNA expression (Figures 5B, C, D, E, F, respectively) was 371 
unaffected by either glycogen availability or the exhaustive exercise protocol (P > 0.05). 372 
 373 
Discussion 374 
Using a sleep-low, train-low model, we examined the effects of three distinct levels of pre-375 
exercise muscle glycogen on exercise capacity and the modulation of selected skeletal muscle 376 
signalling pathways with putative roles in mitochondrial biogenesis. We provide novel data by 377 
demonstrating that 1) graded reductions in pre-exercise muscle glycogen of 100 mmol kg-1 dw 378 
reduce exercise capacity at 80% PPO by ~20-50% and 2) despite significant differences in pre-379 
exercise muscle glycogen availability, we observed comparable increases in AMPKThr172 380 
phosphorylation and PGC-1α mRNA. In contrast to our hypothesis, these data suggest that 381 
graded levels of muscle glycogen below 300 mmol kg-1 dw do not augment skeletal muscle 382 
cell signalling, a finding that may be related to the fact that commencing exercise with <300 383 
mmol kg-1 dw is already a critical level of absolute glycogen (as suggested by Impey et al. (20)) 384 
that is required to induce a metabolic milieu conducive to cell signalling. In relation to the goal 385 
of promoting cell signalling, our data therefore suggest that reducing pre-exercise glycogen 386 
concentrations below 300 mmol kg-1 dw does not confer any additional benefit within the 387 
context of the sleep-low, train-low model.  388 
 389 
To achieve our intended model of graded glycogen concentrations, we adopted a sleep-low, 390 
train-low design whereby subjects performed an evening bout of glycogen depleting exercise 391 
and subsequently ingested three graded quantities of CHO that were practically viable within 392 
the time-course of the sleep-low model. This strategy was effective in achieving graded 393 
differences in pre-exercise muscle glycogen concentration (278 vs. 185 vs. 88 mmol kg-1 dw 394 
in H-CHO, M-CHO and L-CHO, respectively) and represent muscle glycogen resynthesis rates 395 
(approximately 30 mmol kg-1 h-1) commonly observed with CHO feeding rates of 1-1.2 g kg-1 396 
h-1 (21). A novel aspect of our chosen study design was that we employed a sampling point in 397 
both the H-CHO and M-CHO trials that was matched to the point of exhaustion in the L-CHO 398 
trial, thus allowing for the assessment of mitochondrial related signalling events at both work-399 
matched and exhaustive exercise time points, whilst also allowing for the assessment of 400 
exercise capacity. In accordance with differences in muscle glycogen, both NEFA availability 401 
and lipid oxidation were greater in the L-CHO trial when compared with the H-CHO trial at 402 
the work-matched sampling point. However, at the point of exhaustion, plasma NEFA and 403 
glycerol were comparable between all conditions which is likely reflective of the post-exercise 404 
muscle glycogen concentrations in all three conditions given the well documented effects of 405 
muscle glycogen (2) on substrate utilisation during exercise. 406 
 407 
Consistent with the well documented effects of muscle glycogen on exercise capacity (4, 16) 408 
we observed that even small differences in pre-exercise muscle glycogen concentrations (~100 409 
mmol kg-1 dw) can induce changes in exercise capacity at 80% PPO of between ~20-50% (8-410 
18 minutes). Whilst we acknowledge that the lack of blinding to each experimental condition 411 
may have influenced exercise capacity (despite subjects receiving no feedback during 412 
exercise), it is unclear whether prior knowledge of CHO intake alone would enhance exercise 413 
performance (17). Nonetheless, these data are consistent with previous data (1, 6) that suggest 414 
differences in muscle glycogen of 100-120 mmol kg-1 dw enhance exercise capacity at 70% 415 
V̇O2max by 5-12 minutes. As such, the 8 minute difference in exercise capacity between M-416 
CHO and H-CHO trials is likely more representative of changes in muscle glycogen 417 
concentration. Whilst we consider that the present data may help to characterise what is 418 
considered a worthwhile change in absolute muscle glycogen concentration in determining 419 
exercise capacity, we acknowledge these changes should be considered in the context of each 420 
individual given the interindividual variability between subjects in the present study. 421 
Furthermore, as the capacity for glycogen storage is enhanced and its utilisation during exercise 422 
reduced amongst well-trained populations (1, 15, 23) such small differences in muscle 423 
glycogen (as observed within the present study) may allow for extended exercise times amongst 424 
well-trained individuals.  425 
 426 
In relation to post-exercise mitochondrial related signalling, it is widely accepted that 427 
commencing work-matched exercise protocols with reduced muscle glycogen induces greater 428 
skeletal muscle signalling (20). For example, AMPKThr172 phosphorylation (46), AMPK-α2 429 
activity (45) and nuclear abundance (39) are all augmented when acute exercise is commenced 430 
with reduced pre-exercise muscle glycogen. In contrast, we observed no enhancement in 431 
AMPKThr172 or ACCSer79 phosphorylation at our work-matched time point (i.e. following the 432 
completion of ~20 min high-intensity cycling) despite graded reductions in pre-exercise muscle 433 
glycogen concentrations. This apparent lack of augmented cell signalling may be explained by 434 
subjects already commencing exercise with pre-exercise glycogen concentrations below 300 435 
mmol kg-1 dw, an absolute concentration that was previously suggested to facilitate the 436 
enhanced cell signalling responses associated with low glycogen availability (20). Indeed, our 437 
range of pre-exercise muscle glycogen concentrations are distinctly lower than previous work 438 
that report greater skeletal muscle signalling following work-matched exercise protocols. For 439 
example, high glycogen trials are commonly commenced with muscle glycogen concentrations 440 
between 400 and 600 mmol kg-1 dw (3, 36) and remain above 300 mmol kg-1 dw post-exercise 441 
(3, 36, 45). In such instances, these researchers observed attenuated (45) or abolished (3, 36) 442 
activation of cell signalling pathways. Interestingly, despite the completion of significantly 443 
more work in both the M-CHO and H-CHO trials, no further increases in AMPKThr172 444 
phosphorylation were observed following exhaustive exercise. Whilst both AMPK activity and 445 
ACC phosphorylation are known to be regulated by exercise duration (41) these responses 446 
appear to be closely linked to changes in muscle glycogen concentrations (9, 41). With this in 447 
mind, the lack of augmented signalling in response to further exercise in the present study may 448 
be explained by the relatively small changes in muscle glycogen from the work-matched time 449 
point to exhaustion.  450 
 451 
In contrast to AMPK and ACC, we did not observe any change in the phosphorylation status 452 
of p38MAPKThr180/Tyr182 or CAMKII Thr286 either in response to exercise or muscle glycogen 453 
concentration, though we note the large inter-individual variability and recommend the use of 454 
larger sample sizes in future. These data are in agreement with previous work that demonstrate 455 
no change in p38MAPK or CAMKII phosphorylation using a variety of train-low 456 
methodologies, including sleep-low, train-low (3, 25), twice-per day training (46) and fasted 457 
training (42). Whilst augmented p38MAPK phosphorylation has been observed when pre-458 
exercise muscle glycogen is reduced (163 vs. 375 mmol kg-1 dw), this is only apparent within 459 
the nucleus and not the cytoplasm (7). As such, further work should utilise cellular fractionation 460 
methodologies in order to investigate the cellular localisation of such exercise-inducible 461 
kinases.  462 
 463 
Despite the observed augmented mRNA expression of PGC-1α within the post-exercise 464 
recovery period, exhaustive exercise did not augment the mRNA expression of other 465 
mitochondrial (p53 or Tfam) or substrate utilization related genes (PDK4, CPT1 or CD36). 466 
Although the time-course of mRNA expression for these genes is not well understood, the lack 467 
of change in mRNA expression in the present study may be explained by our chosen sampling 468 
points in accordance with our sleep-low, train-low exercise model. Indeed, given that our pre-469 
exercise biopsy was sampled within ~14 h of glycogen depleting exercise, it is difficult to 470 
determine whether mRNA expression was already elevated at pre-exercise. For instance, time-471 
course studies have revealed that the mRNA expression of Tfam (31), PDK4 and CPT1 (34) is 472 
enhanced for up to 24 h post-exercise which coincides with our pre-exercise sampling time 473 
point (~14 h between the two exercise bouts). However, given the time-course of 474 
phosphorylation of our chosen protein targets (8) it is highly unlikely that any of these proteins 475 
would be phosphorylated at pre-exercise as a result of the previous evenings glycogen depletion 476 
exercise.  477 
 478 
Practically, these data suggest that in the context of the sleep-low, train-low model, where 479 
muscle glycogen is depleted to very low levels (~100 mmol kg-1 dw), insufficient time is 480 
available to restore muscle glycogen to normal levels. As such, individuals undertaking sleep-481 
low, train-low models, that reduces muscle glycogen to very low levels, should consume CHO 482 
in accordance with the energetic requirements of the subsequent morning session, given that 483 
withholding CHO intake overnight appears to confer no additional benefit in relation to cell 484 
signalling but impairs exercise capacity. In contrast, it appears that when muscle glycogen is 485 
not depleted to such low levels (> 300 mmol kg-1 dw), withholding CHO intake in the post-486 
exercise period may prolong the acute cell signalling and gene expression responses (25, 34). 487 
With this in mind, it should be noted that driving glycogen depletion below 300 mmol kg-1 dw 488 
would likely be more difficult and require considerably more work in well-trained individuals 489 
(11) given they display an enhanced capacity for glycogen storage and reduced utilisation 490 
during exercise (1, 15, 23). In practice, it appears that careful consideration of the individuals 491 
training status and the metabolic demands of each training session is required to ensure 492 
appropriate day-to-day periodisation of CHO in order to ensure absolute training intensity is 493 
not compromised whilst also creating a metabolic milieu conducive to facilitating the metabolic 494 
adaptations associated with ‘train low’. 495 
 496 
In summary, we provide novel data by demonstrating that graded reductions in pre-exercise 497 
muscle glycogen below 300 mmol kg-1 dw (as achieved using a sleep-low, train-low model) 498 
impairs exercise capacity but does not augment skeletal muscle cell signalling responses. 499 
Practically, our data suggest that, within the context of the sleep-low, train-low model (when 500 
muscle glycogen is depleted to very low levels) overnight CHO restriction is not required to 501 
augment skeletal muscle cell signalling, and thus, CHO should be consumed in accordance 502 
with the metabolic demands of the subsequent morning session. Future studies should 503 
investigate step-wise reductions in pre-exercise muscle glycogen, within a wider range (i.e. 504 
100-600 mmol kg-1 dw), in order to investigate the existence of a potential glycogen threshold 505 
(20) and allow for a better definition of its potential upper and lower limits.  506 
 507 
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Figure legends 665 
 666 
Figure 1. Schematic overview of the experimental sleep-low, train-low protocol. Following 24 667 
h of standardised dietary conditions, subjects completed an evening bout of glycogen depleting 668 
cycling exercise. Upon completion, subjects received three graded levels of CHO in order to 669 
manipulate pre-exercise muscle glycogen the subsequent morning. Following an overnight fast, 670 
subjects completed an exhaustive bout of cycling exercise. Muscle biopsies were obtained pre-671 
exercise, at the point of exhaustion (post exercise) and 3 h post exercise. During H-CHO and 672 
M-CHO trials, an additional muscle biopsy was obtained at a time point corresponding to the 673 
point of exhaustion in the L-CHO trial, allowing for work-matched comparison between trials. 674 
 675 
Figure 2. (A) Skeletal muscle glycogen concentration and (B) Exercise capacity at 80% PPO 676 
(reflective of set work protocol plus time to exhaustion). #P < 0.05, significantly different from 677 
pre-exercise, §P < 0.05, significantly different from H-CHO, ‡P < 0.05, significantly different 678 
from M-CHO. Data is presented as means and individual data points represent individual 679 
subjects. N=8 680 
 681 
Figure 3. (A) Heart rate, (B) RPE and plasma (C) Glucose, (D) Lactate, (E) NEFA (F) glycerol 682 
pre-exercise, at work-matched time points and post-exercise, (E) Average CHO and (F) lipid 683 
oxidation during exercise. #P < 0.05, significantly different from pre-exercise, §P < 0.05, 684 
significantly different from H-CHO. Data is presented as mean ± SD (A-D) and individual data 685 
points represent individual subjects (E & F). N=8  686 
 687 
Figure 4. (A) AMPKThr172 phosphorylation, (B) ACCSer79 phosphorylation, (C) p38Thr180/Tyr182 688 
phosphorylation, (D) CaMKIIThr286 phosphorylation and (E) representative Western blot 689 
images at pre-exercise, work-matched time point and post-exercise. #P < 0.05, significantly 690 
different from pre-exercise, *P < 0.05, significantly different from L-CHO. Data is presented 691 
as means and individual data points represent individual subjects. N=7 692 
Figure 5. (A) PGC-1α, (B) p53, (C) Tfam, (D) CPT-1, (E) CD36 and (F) PDK4 mRNA 693 
expression pre- and 3 h post-exercise. #P < 0.05, significantly different from pre-exercise. Data 694 
is presented as means and individual data points represent individual subjects. N=8 695 
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Table 1. Primers used for real-time RT-PCR  728 
 729 
Gene Forward primer Reverse primer 
PGC-1 TGCTAAACGACTCCGAGAA TGCAAAGTTCCCTCTCTGCT 
p53 ACCTATGGAAACTACTTCCTGAAA CTGGCATTCTGGGAGCTTCA 
Tfam TGGCAAGTTGTCCAAAGAAACCTGT GTTCCCTCCAACGCTGGGCA 
CD36 AGGACTTTCCTGCAGAATACCA ACAAGCTCTGGTTCTTATTCACA 
PDK4 TGGTCCAAGATGCCTTTGAGT GTTGCCCGCATTGCATTCTT 
CPT1 GACAATACCTCGGAGCCTCA AATAGGCCTGACGACACCTG 
GAPDH AAGACCTTGGGCTGGGACTG TGGCTCGGCTGGCGAC 
 
